2019-04-26 Regulatory

NeoDynamics AB (publ) receives advance notice from U.S. Patent Office for a granted biopsy instrument patent

NeoDynamics AB (publ) has received notification, a “Notice of Allowance”, from the US Patent Authority that patent will be granted provided that the grant fee is paid

The announcement from the US patent authority means that NeoDynamic's unique biopsy device with front-loaded needle and integrated trocar, an important component of the NeoNavia® biopsy system, will be approved shortly. The patent increases the protection of the NeoNavia biopsy system, which further strengthens the competitiveness.

“This notice is very positive for our shareholders. The American market is the single largest biopsy market and an important part of our global strategy. Together with our other patents this is a confirmation of our unique technology and a good springboard for our upcoming registration and launch in the US. The focus on our biopsy system means that we offer several different needle types with different functions, all with micropulse technology. This patent is important as it further increases the protection of one of our needle types. This micropulse needle type enables the radiologist to get reliable tissue samples with high quality. The patented needle function is currently used in the products used in our clinical studies in Europe. The launch of the biopsy system will commence early 2020, as soon as we receive regulatory approvals in the EU and the US.”, says Anna Eriksrud, CEO of NeoDynamics.